At least 12 biotechs and pharmas are slated to report earnings this week. Vivus Inc. (NASDAQ:VVUS) will report the second full quarter of sales of obesity drug Qsymia phentermine/topiramate. The Street is expecting $5.2 million in revenues. Qsymia was launched last September, and had $2 million in 4Q12 revenues. Vivus is also anticipated to report a loss per share of $0.51 vs. a loss per share of $0.20 in 1Q12, as SG&A has escalated due to the drug launch.